Piracetam

Supplements · Nootropics · Supplement, Typed Supps

The first drug ever called a "nootropic," used by prescription in some European countries for cognitive symptoms — but the FDA says it isn’t allowed to be sold as a US supplement, and good evidence it actually boosts thinking is hard to find.

Stage by stage

Intake (Tablet or capsule): Taken orally, historically at gram-level clinical doses.
Absorption (Gut): Absorbed into the bloodstream with high bioavailability.
Bloodstream (Circulates): Crosses into the brain and affects red blood cell flow properties.
Brain (Proposed neuronal effects): Proposed to affect neuronal membranes and neurotransmitter receptors, though the mechanism remains debated.

What the evidence supports

Improving cognition in dementia or age-related cognitive decline — insufficient evidence. A Cochrane review found published evidence did not support piracetam’s use for dementia or cognitive impairment; while some effect was seen on global clinical impression, specific cognitive function measures showed no benefit. A 2024 systematic review and meta-analysis likewise concluded piracetam does not yield significant cognitive enhancement.
Enhancing cognitive performance in healthy adults — insufficient evidence. There is no solid modern trial evidence that piracetam meaningfully improves memory, focus, or other cognitive measures in healthy people — most of the historical trial base is in cognitively impaired or elderly patients, not healthy supplement users.
Evidence on US regulatory status as a dietary supplement ingredient — insufficient evidence. The FDA rejected a new dietary ingredient notification for piracetam in the mid-2000s and has since issued warning letters (including to companies marketing it alongside other racetams) stating it does not qualify as a legal dietary supplement ingredient in the US and is not an approved drug here either — the same regulatory gray zone documented for noopept.

Typical dose

Historical clinical trials and prescription use in Europe (where it remains available by prescription in several countries) have used 1.2–4.8g/day in divided doses; there is no standardized US supplement dose because it is not a recognized supplement ingredient.

Upper limit: No established UL relevant to US supplement use, given its non-supplement status.

Timing

No FDA-endorsed dosing guidance exists given its regulatory status.

Time to effect

Unclear: The Cochrane review and subsequent meta-analyses found no consistent cognitive benefit, so no reliable time-to-effect can be given.

Common myth

“Piracetam is a proven, legal cognitive-enhancement supplement.” In reality: The FDA has issued warning letters stating piracetam does not qualify as a legal dietary supplement ingredient in the US, and a Cochrane review plus more recent meta-analyses have found it does not reliably improve cognition on objective measures, even in the impaired populations where it has been most studied.